CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 91 - 100 of 1138
Study Number Lead Group Study Title CIRB Study Status
10334 ETCTN BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) who are Ineligible or who Refuse Intensive Chemotherapy Adult CIRB - Early Phase Emphasis Available to Open
10335 ETCTN A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Adult CIRB - Early Phase Emphasis Available to Open
10346 ETCTN Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10347 ETCTN A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS) Adult CIRB - Early Phase Emphasis Available to Open
10349 ETCTN A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas Adult CIRB - Early Phase Emphasis Completed
10355 ETCTN A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies Adult CIRB - Early Phase Emphasis Available to Open
10358 ETCTN Phase 1/1B study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial) Adult CIRB - Early Phase Emphasis Available to Open
10366 ETCTN A Phase 1/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma Adult CIRB - Early Phase Emphasis Available to Open
10367 ETCTN A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML) Adult CIRB - Early Phase Emphasis Available to Open
10371 ETCTN A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response Adult CIRB - Early Phase Emphasis Available to Open
Displaying 91 - 100 of 1138